The Market for Prenatal, Newborn and Carrier Genetic Testing: Forecasts to 2019

Attention: There is an updated edition available for this report.
   Single User - $1,995
   Site License (one location, 10 users) - $2,995
   Corporate License - $3,995

Published May 1, 2015 | 269 Pages | Pub ID: KLI5546954

The Market for Prenatal, Newborn and Carrier Genetic Testing

The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing global genetic testing laboratory services market is discussed, including:
  • carrier testing
  • prenatal testing
  • newborn screening
  • neonatal/pediatric testing
  • testing for adult onset genetic disorders
The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis – from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The technologies used for newborn screening discussed in the report include:
  • Karyotyping
  • Fluorescence in situ Hybridization
  • Chromosomal Microarrays
  • Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies
  • DNA Sequencing
  • Mass Spectrometry
  • Conventional versus Non-Invasive Prenatal Testing
The Market for Prenatal, Newborn and Carrier Genetic Testing provides the world markets for prenatal, newborn, postnatal, and carrier genetic testing for 2014 to 2019. In addition, company revenues are provided for the previous three years. Further, this report includes financial information on deals involving companies in the molecular diagnostic inherited disease/prenatal testing field, summarized within report tables.

Prenatal testing can be used to identify fetuses with chromosomal abnormalities or genetic mutations that would result in the birth of an affected newborn. Women who are experience recurrent miscarriages can be tested to determine if there is a genetic cause, if their fetuses could not survive due to an inherited disorder. Children may also be tested, often to identify the cause of developmental or intellectual delay. These and other applications of inherited disease testing are discussed in the report.

The report also discusses
  • Genetic Testing Services Market
  • Diagnostic Kits
Currently in vitro diagnostic companies are developing or marketing molecular diagnostic kits to clinical laboratories, and also many clinical laboratories have developed laboratory developed tests (LDTs) and are offering genetic testing services to aid physicians as they diagnose patients with these genetic disorders. Other applications of genetic testing, including preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) assays used before in vitro fertilization, and also the direct-to-consumer genetic testing market, are discussed as well.

Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include:
  • 23andMe, Inc.
  • AB SCIEX (A Danaher Corporation Company)
  • Abbott Laboratories
  • Affymetrix, Inc.
  • Agena Bioscience Inc.
  • Agilent Technologies Inc.
  • Ambry Genetics Corp.
  • ARUP Laboratories
  • Astra Biotech GmbH
  • Asuragen, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • AutoGenomics, Inc.
  • Berry Genomics Co., Ltd.
  • BGI-Shenzhen
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories, Inc. (BRLI)
  • Centogene AG
  • Chromsystems Instruments & Chemicals GmbH
  • Claritas Genomics, Inc.
  • Color Genomics, Inc.
  • CombiMatrix Corporation
  • Counsyl, Inc.
  • Courtagen Life Sciences, Inc.
  • GenapSys
  • Gene by Gene, Ltd.
  • Genection, Inc. (An Invivoscribe Company)
  • GeneDx
  • GenePeeks, Inc.
  • Genesis Genetics
  • Genetadi Biotech S.L.
  • Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division)
  • GenMark Diagnostics, Inc.
  • Genoma Group
  • Genomed AG
  • GenPath / GenPath Women’s Health
  • Good Start Genetics, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Innovations Exchange Pte Ltd (INEX) and iGene™ Diagnostics Pte Ltd (an INEX Company)
  • Invitae Corporation
  • Laboratory Corporation of America (LabCorp) Integrated Genetics
  • Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
  • LifeCodexx AG (Subsidiary of GATC Biotech AG)
  • Multiplicom NV
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NewGene Ltd.
  • NIPD Genetics, Ltd.
  • Oxford Gene Technology
  • Parabase Genomics
  • Pathway Genomics Corporation
  • PerkinElmer, Inc.
  • Premaitha Health
  • Progenity, Inc.
  • Quest Diagnostics
  • Ravgen
  • Recombine, Inc.
  • Reproductive Genetics Institute
  • Reprogenetics
  • Roche
  • Sebia, Inc.
  • Sequenom, Inc.
  • Sophia Genetics
  • SpOtOn Clinical Diagnostics Limited
  • SynapDx Corporation
  • Transgenomic, Inc.
The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.